Theravance Biopharma Inc.’s phase IIb fizzle with izencitinib in ulcerative colitis (UC) put a dent in shares, as Wall Street mulled the ongoing phase II study in Crohn’s disease (CD) as well as prospects regarding the deal with Johnson & Johnson.
As talk increases of third doses of COVID-19 vaccine, a game-changing option is delivering them intranasally instead of intramuscularly. “It’s all about nasal carriage. It’s a better way to not carry the virus and not make others sick,” Bluewillow Biologics Inc. CEO Chad Costley told BioWorld. “The most important thing is that it’s safe.”
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bavarian Nordic, Foghorn, Hepagene, Kezar, Lexicon, Orphazyme Plus, Puretech, Sen-Jam.
Adlai Nortye Biopharma Co. Ltd.’s $100 million series D financing in July threw new light on the enticing prospect of targeting EP4 in prostaglandin (PGE2)-driven cancers, and a number of players are lined up in the space.
Astrazeneca plc, en route to potentially delivering a new protection against COVID-19 for people inadequately protected by or unable to be vaccinated, has cleared a crucial hurdle with its long-acting combination therapy, AZD-7442, which met the goals of a phase III pre-exposure prophylaxis trial. The U.K.-based pharma’s readout arrived just as Regeneron Pharmaceuticals Inc. announced the MHRA’s conditional marketing authorization for its Roche Holding AG-partnered COVID-19 antibody therapy Ronapreve (casirivimab + imdevimab), also known as REGEN-COV.
A month after Astrazeneca plc’s $39 billion takeover of Alexion Pharmaceuticals Inc. was finalized, the merged company has hit its first speed bump after the new unit discontinued a phase III rare disease trial. Alexion, of Boston, said it axed the 382-patient CHAMPION-ALS trial of its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in amyotrophic lateral sclerosis (ALS).
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Coherus, Compugen, Intrabio, Janssen, Junshi, Nervgen, Nrx, Scioto, Zealand, Zhaoke.
LONDON – The latest data from the large-scale randomized U.K. COVID-19 infection survey confirm vaccines are less effective against the Delta variant of SARS-CoV-2 that is now dominant across the U.S., Europe and elsewhere in the world.
RSS
